US Appeals Court Sends UC Berkeley, Broad Institute Back to the Mat in CRISPR-Cas9 Patent Dispute
Premium
It is unclear how the decision will eventually affect Editas Medicine and other companies relying on CRISPR-based technologies and products.
Following a joint statement from the two countries on Monday, stocks of major life sciences tool and diagnostic companies rallied.
Metastatic Prostate Cancer Study Underscores Precision Medicine Potential in Diverse US Veterans
Researchers profiled somatic changes in tumor samples from thousands of US veterans with metastatic prostate cancer, identifying alterations with varied representation by ancestry.
Quanterix Cuts 2025 Guidance Due to Tariffs, Academic Funding, as Q1 Revenues Fall 5 Percent
Premium
The company lowered its 2025 revenue guidance to between $120.0 million and $130.0 million, representing a year-over-year decline of 5 percent to 13 percent.
MantaBio Nabs $2.5M in Seed Funding to Develop Microbial Detection Platform for Biopharma
The Beverly, Massachusetts-based startup is commercializing an automated qPCR instrument for microbial contamination testing targeting biopharma customers.
Pluto Bio Raises $3.6M to Grow Adoption of Multiomics Analysis Platform by Pharma
With its third funding round complete, the Wyss Institute spinout intends to scale up its AI-based research and development tools.
The firm booked $154.9 million in Q1 revenues, including $16.8 million in license and royalty revenues from the patent litigation settlement with Vizgen.
The firm expects 2025 revenues to shrink versus the prior year and business in China to dry up over the course of the year.